{
    "nctId": "NCT06621459",
    "briefTitle": "Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)",
    "officialTitle": "Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data",
    "overallStatus": "RECRUITING",
    "conditions": "Brest Cancer, Abemaciclib, Adjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "the average dose of abemaciclib received over 6 months.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patient\n* Patient who has received adjuvant ABEMACICLIB in combination with hormone therapy\n* Patient with localized RH+ HER2 non-amplified breast cancer and eligible for treatment with ABEMACICLIB according to the recommendations of the MA (Marketing Authorization) as defined below:\n\n  * 4 ipsilateral positive axillary lymph nodes OR\n\n    1. to 3 ipsilateral positive axillary lymph node(s) with at least one of the following two criteria: histological grade 3 or primary tumor size \u22655 cm\n\nExclusion Criteria:\n\n* Patients under legal protection (guardianship, trusteeship, etc.)\n* Refusal to participate",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}